Rising Prevalence Of Helicobacter Pylori Infection Driving The Market Growth Due To Increasing Risk Of Gastric Complications And Cancer Is Supporting Development Across The Gastric Cancer Therapy Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

By 2030, How Much Growth In Market Size Is Expected For The Gastric Cancer Therapy Market?

The gastric cancer therapy market has observed substantial expansion in recent years. It is anticipated to increase from $4.5 billion in 2025 to $4.92 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.3%. The market’s historical development can be credited to factors like the restricted availability of targeted therapies, the continued dependence on traditional chemotherapy and surgical treatments, the increasing prevalence of gastric cancer, the expanding oncology infrastructure within hospitals, and improved awareness regarding early detection initiatives.

The gastric cancer therapy market is anticipated to show significant expansion in the coming years, with its value set to reach $6.96 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.1%. This projected increase is attributable to the development of innovative immunotherapies and checkpoint inhibitors, a growing embrace of precision medicine, the expansion of outpatient oncology services, increased funding for gastric cancer research, and the integration of digital health tools for patient monitoring. Prominent trends expected during this period include a heightened adoption of targeted and personalized therapies, an increase in combination therapy strategies, an improvement in early detection and screening initiatives, the growth of home care and ambulatory treatment alternatives, and a concentrated effort on reducing adverse effects and enhancing patient quality of life.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25767&type=smp

Which Growth Factors Are Strengthening The Gastric Cancer Therapy Market Landscape?

An increase in Helicobacter pylori infection cases is anticipated to drive expansion in the gastric cancer therapy market in the future. Helicobacter pylori infection, a bacterial condition predominantly impacting the stomach lining, is a significant contributor to chronic gastritis and gastric cancer. This growing incidence is largely linked to inadequate sanitation, given that insufficient hygiene and polluted food or water enable the bacteria’s oral-oral or fecal-oral spread. Gastric cancer therapy aids in lowering the risk of gastric cancer resulting from Helicobacter pylori infection through direct treatment of the infection, lessening related stomach inflammation and cell damage, and halting the advancement of chronic gastritis and atrophic alterations that could lead to the malignant transformation of the gastric mucosa. For example, a report released by the Government of Canada, a Canada-based government administration, in November 2024, indicated that as of January 2023, the H. pylori infection recurrence rate could be as high as 19%, though regional and age variations exist. Consequently, the increasing occurrence of Helicobacter pylori infection is fueling expansion in the gastric cancer therapy market.

Which Segment Divisions Form The Structure Of The Gastric Cancer Therapy Market?

The gastric cancer therapy market covered in this report is segmented –

1) By Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery

2) By Drug Class: Cytotoxic Agents, Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Checkpoint Inhibitors, Miscellaneous Agents

3) By Administration Route: Oral, Intravenous, Intramuscular, Subcutaneous

4) By Stage of Disease: Early Stage, Locally Advanced Stage, Metastatic Stage

5) By End User: Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Research Institutions, Home Care Settings

Subsegments:

1) By Chemotherapy: Neoadjuvant Chemotherapy (NAC), Adjuvant Chemotherapy (AC), Palliative Chemotherapy (PC), Combination Chemotherapy, Monotherapy

2) By Targeted Therapy: Human Epidermal Growth Factor Receptor 2 (HER2) Targeted Therapy, Vascular Endothelial Growth Factor (VEGF) Inhibitors, Fibroblast Growth Factor Receptor (FGFR) Inhibitors, Mesenchymal-Epithelial Transition (MET) Inhibitors, Claudin 18 Isoform 2 Inhibitors

3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Adoptive Cell Transfer, Cytokine Therapy, Combination Immunotherapy

4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT), Three-Dimensional Conformal Radiation Therapy (3D-CRT), Brachytherapy

5) By Surgery: Endoscopic Mucosal Resection (EMR), Endoscopic Submucosal Dissection (ESD), Subtotal Gastrectomy, Total Gastrectomy, Lymphadenectomy

What Trends Are Driving Changes In The Gastric Cancer Therapy Market?

Leading companies within the gastric cancer therapy market are concentrating on developing innovative treatments, such as combination therapy, to improve treatment efficacy and patient outcomes. This therapeutic approach involves utilizing two or more treatments, like chemotherapy, targeted therapy, or immunotherapy, in conjunction to enhance overall effectiveness. For instance, in December 2024, BeOne Medicines Ltd., a China-based pharmaceutical company formerly known as BeiGene, obtained approval from the U.S. Food and Drug Administration (FDA) for Tevimbra (tislelizumab-jsgr) in combination with platinum- and fluoropyrimidine-based chemotherapy. This approval is for the first-line treatment of adults diagnosed with unresectable or metastatic HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma whose tumors express PD-L1 (=1). This regulatory decision stemmed from data derived from the Phase 3 RATIONALE-305 trial, which demonstrated that the combination therapy considerably improved median overall survival to 15.0 months, contrasting with 12.9 months when using chemotherapy alone, thereby representing a 20% reduction in the risk of death. This significant event emphasizes an escalating trend among major pharmaceutical firms to invest in innovative, multimodal treatment strategies that integrate immunotherapy with conventional chemotherapy regimens to enhance clinical outcomes, delay disease progression, and improve survival rates for patients suffering from advanced gastric cancer.

Who Are The Businesses Driving Activity In The Gastric Cancer Therapy Market?

Major companies operating in the gastric cancer therapy market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene Ltd., Celltrion Healthcare Co. Ltd., Hutchison MediPharma Limited, Shanghai Henlius Biotech Inc.

Access The Complete Gastric Cancer Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-therapy-global-market-report

Which Regional Market Leads The Gastric Cancer Therapy Market?

North America was the largest region in the gastric cancer therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Gastric Cancer Therapy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=25767&type=smp

Browse Through More Reports Similar to the Global Gastric Cancer Therapy Market 2026, By The Business Research Company

Gastric Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Gastric Cancer Diagnostic Procedure Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastric-cancer-diagnostic-procedure-global-market-report

Intestine Cancer Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/intestine-cancer-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795